Camurus AB (CAMX) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

During the questions and answer session, participants on the telco are able to ask questions by dialing pound key five on the telephone keypad. Now I will hand the conference over to CEO Fredrik Thibald. Please go ahead. Thank you so much and good day everyone and welcome to Canberra's second quarter 2026 result call. Thank you for joining us. Before we begin, please take note of our forward-looking statements which apply throughout today's presentation. Turning to the agenda, we will start with highlights, moving over to financial and commercial performance reviews, before finishing with a short R&D pipeline update, key takeaways, and then of course Q&A. With me on the call today are Anders Wadsholt, our Chief Financial Officer, and Richard Jameson, our Chief Commercial Officer. So let me start with some highlights. I'm very pleased to report a solid second quarter, marking a clear return to growth after a softer start of the year for cameras. Total revenues were 702 million SEK, up 4% year-on-year and 32% sequentially, with an operating result of 293 million SEK, corresponding to a 42% margin and finishing with 4.1 billion SEK in cash. Commercially, product sales reached a record of 528 million SEK. It's the first time we are above half a billion in a quarter. Buvidal grew 12% year-on-year and 24% over the quarter. Bixadi royalties in the U.S. increased 42%, and the OxyVisa launch continued in our first wave European markets. In the pipeline, we received a complete response letter for the acromegaly NDA in the U.S. in June, which I will cover and come back to later in the presentation. Elsewhere, Sorrento continued to progressing towards its primary analysis. We advanced CAM 2056 phase 2b preparations. Lilly expanded our collaboration by exercising its option to in...